89 related articles for article (PubMed ID: 17068880)
21. Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice.
Zafeirakis A; Zissimopoulos A; Baziotis N; Limouris GS
Cancer Biother Radiopharm; 2009 Oct; 24(5):543-50. PubMed ID: 19877884
[TBL] [Abstract][Full Text] [Related]
22. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.
Han SH; de Klerk JM; Tan S; van het Schip AD; Derksen BH; van Dijk A; Kruitwagen CL; Blijham GH; van Rijk PP; Zonnenberg BA
J Nucl Med; 2002 Sep; 43(9):1150-6. PubMed ID: 12215552
[TBL] [Abstract][Full Text] [Related]
23. Application of rhenium-188 HEDP in bone metastases therapy.
Scheffler J; Derejko M; Bandurski T; Romanowicz G
Nucl Med Rev Cent East Eur; 2003; 6(1):55-7. PubMed ID: 14600935
[TBL] [Abstract][Full Text] [Related]
24. The use of radioisotopes for palliation of metastatic bone pain.
Gkialas I; Iordanidou L; Galanakis I; Giannopoulos S
J BUON; 2008; 13(2):177-83. PubMed ID: 18555462
[TBL] [Abstract][Full Text] [Related]
25. Radioisotopes in the treatment of bone metastases.
Ben-Josef E; Porter AT
Ann Med; 1997 Feb; 29(1):31-5. PubMed ID: 9073322
[TBL] [Abstract][Full Text] [Related]
26. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases.
Pandit-Taskar N; Batraki M; Divgi CR
J Nucl Med; 2004 Aug; 45(8):1358-65. PubMed ID: 15299062
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
Kolesnikov-Gauthier H; Carpentier P; Depreux P; Vennin P; Caty A; Sulman C
J Nucl Med; 2000 Oct; 41(10):1689-94. PubMed ID: 11037999
[TBL] [Abstract][Full Text] [Related]
28. X-ray of the month. I. Metastatic carcinoma of prostate.
J Maine Med Assoc; 1969 Jan; 60(1):22. PubMed ID: 5764752
[No Abstract] [Full Text] [Related]
29. Radionuclide therapy for prostate cancer lumbar metastasis prolongs symptom-free survival in a rat model.
Geldof AA; van den Tillaar PL; Newling DW; Teule GJ
Urology; 1997 May; 49(5):795-801. PubMed ID: 9145995
[TBL] [Abstract][Full Text] [Related]
30. [The role of bone scintigraphy and its value in the staging and follow up of prostatic carcinoma].
Adám E; Gervain M; Rajtár M; Oszlánczi J; Csernay L; Scultéty S
Orv Hetil; 1989 Feb; 130(7):335-40. PubMed ID: 2645558
[TBL] [Abstract][Full Text] [Related]
31. Serum hemoglobin levels predict response to strontium-89 and rhenium-186-HEDP radionuclide treatment for painful osseous metastases in prostate cancer.
van der Poel HG; Antonini N; Hoefnagel CA; Horenblas S; Valdes Olmos RA
Urol Int; 2006; 77(1):50-6. PubMed ID: 16825816
[TBL] [Abstract][Full Text] [Related]
32. [Osseous metastases of cancer of the prostate: frequency of osteolytic forms].
Louyot P; Gaucher A; Combebias JF; Manivit P
J Radiol Electrol Med Nucl; 1968 Dec; 49(12):903-8. PubMed ID: 4179419
[No Abstract] [Full Text] [Related]
33. [Radiotherapy of the prostate carcinoma (author's transl)].
von Rottkay P; Lössl HJ; Böhm O
Strahlentherapie; 1978 Dec; 154(12):820-9. PubMed ID: 725967
[TBL] [Abstract][Full Text] [Related]
34. New approaches to the use of unsealed source radionuclide therapy for skeletal metastases.
McCready VR; O'Sullivan JM
Kaku Igaku; 2002 Sep; 39(3):249-50. PubMed ID: 12449556
[No Abstract] [Full Text] [Related]
35. Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients.
Zhang H; Tian M; Li S; Liu J; Tanada S; Endo K
Cancer Biother Radiopharm; 2003 Oct; 18(5):719-26. PubMed ID: 14629820
[TBL] [Abstract][Full Text] [Related]
36. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
de Klerk JM; van Dieren EB; van het Schip AD; Hoekstra A; Zonnenberg BA; van Dijk A; Rutgers DH; Blijham GH; van Rijk PP
J Nucl Med; 1996 Jan; 37(1):38-41. PubMed ID: 8543998
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations.
de Klerk JM; van het Schip AD; Zonnenberg BA; van Dijk A; Stokkel MP; Han SH; Blijham GH; van Rijk PP
J Nucl Med; 1994 Sep; 35(9):1423-8. PubMed ID: 8071686
[TBL] [Abstract][Full Text] [Related]
38. Advanced prostate cancer diagnosis and therapy with gallium-67 and yttrium-90, respectively.
Shukla SK; Limouris GS; Cusumano R; Acconcia A; Cipriani C; Atzei G; Argirò G; Boemi S
Anticancer Res; 1997; 17(3B):1731-4. PubMed ID: 9179226
[TBL] [Abstract][Full Text] [Related]
39. Rhenium-186 HEDP as a boost to external beam irradiation in osteosarcoma.
Sawyer EJ; Cassoni AM; Waddington W; Bomanji JB; Briggs TW
Br J Radiol; 1999 Dec; 72(864):1225-9. PubMed ID: 10703485
[TBL] [Abstract][Full Text] [Related]
40. [Analgesic response and secondary effects in patients with osteoblastic metastasis, treated with Samarium 153 ethylenediaminotetramethylenephosphate].
Lovera C; Massardo T; Galleguillos MC; González P; Comparini B; Yáñez M; Fodor M; Gil MC; Araya G; Tomicic M
Rev Med Chil; 1998 Aug; 126(8):963-71. PubMed ID: 9830748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
